Guizhou Yibai Pharmaceutical Co Ltd (600594) — Cash Flow-to-Debt Ratio
Guizhou Yibai Pharmaceutical Co Ltd (600594) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of CN¥33.28 Million could theoretically repay 0% of its total liabilities (CN¥1.32 Billion) in one year. See Guizhou Yibai Pharmaceutical Co Ltd financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Guizhou Yibai Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2002–2025)
Historical debt coverage capacity for Guizhou Yibai Pharmaceutical Co Ltd across 24 annual periods. For the full cash flow conversion analysis, see Guizhou Yibai Pharmaceutical Co Ltd cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Guizhou Yibai Pharmaceutical Co Ltd (2002–2025)
Year-by-year debt coverage analysis for Guizhou Yibai Pharmaceutical Co Ltd. Check 600594 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.22x | CN¥256.71 Million | CN¥1.17 Billion | ▲ +276.8% |
| 2024 | 0.06x | CN¥86.87 Million | CN¥1.49 Billion | ▼ -75.7% |
| 2023 | 0.24x | CN¥377.61 Million | CN¥1.58 Billion | ▲ +16.1% |
| 2022 | 0.21x | CN¥345.30 Million | CN¥1.68 Billion | ▼ -66.8% |
| 2021 | 0.62x | CN¥934.21 Million | CN¥1.51 Billion | ▲ +198.4% |
| 2020 | 0.21x | CN¥366.66 Million | CN¥1.76 Billion | ▲ +8.6% |
| 2019 | 0.19x | CN¥362.71 Million | CN¥1.89 Billion | ▲ +129.1% |
| 2018 | 0.08x | CN¥214.30 Million | CN¥2.56 Billion | ▼ -68.7% |
| 2017 | 0.27x | CN¥681.78 Million | CN¥2.55 Billion | ▲ +68.1% |
| 2016 | 0.16x | CN¥380.62 Million | CN¥2.40 Billion | ▼ -43.6% |
| 2015 | 0.28x | CN¥573.68 Million | CN¥2.04 Billion | ▲ +7.7% |
| 2014 | 0.26x | CN¥541.58 Million | CN¥2.07 Billion | ▼ -42.5% |
| 2013 | 0.46x | CN¥577.24 Million | CN¥1.27 Billion | ▲ +15.6% |
| 2012 | 0.39x | CN¥288.01 Million | CN¥731.33 Million | ▼ -5.7% |
| 2011 | 0.42x | CN¥277.83 Million | CN¥665.51 Million | ▲ +148.6% |
| 2010 | 0.17x | CN¥115.66 Million | CN¥688.82 Million | ▼ -7.7% |
| 2009 | 0.18x | CN¥103.88 Million | CN¥571.26 Million | ▼ -40.4% |
| 2008 | 0.30x | CN¥189.26 Million | CN¥620.62 Million | ▲ +1458.1% |
| 2007 | 0.02x | CN¥11.94 Million | CN¥610.24 Million | ▼ -88.5% |
| 2006 | 0.17x | CN¥95.77 Million | CN¥562.27 Million | ▲ +539.5% |
| 2005 | 0.03x | CN¥17.38 Million | CN¥652.65 Million | ▲ +121.5% |
| 2004 | -0.12x | CN¥-44.80 Million | CN¥361.10 Million | ▼ -137.0% |
| 2003 | 0.34x | CN¥92.10 Million | CN¥274.93 Million | ▼ -20.3% |
| 2002 | 0.42x | CN¥73.46 Million | CN¥174.87 Million | — |